(Q39277523)

10 September 2017

Downregulation of miR-144 is associated with colorectal cancer progression via activation of mTOR signaling pathway (English)

1 reference

10 September 2017

1 reference

1 reference

Takeshi Iwaya

1

1 reference

10 September 2017

Takehiko Yokobori

2

1 reference

10 September 2017

Naohiro Nishida

3

1 reference

10 September 2017

Ryunosuke Kogo

4

1 reference

10 September 2017

Tomoya Sudo

5

1 reference

10 September 2017

Fumiaki Tanaka

6

1 reference

10 September 2017

Kohei Shibata

7

1 reference

10 September 2017

Genta Sawada

8

1 reference

10 September 2017

Yusuke Takahashi

9

1 reference

10 September 2017

Masahisa Ishibashi

10

1 reference

10 September 2017

Go Wakabayashi

11

1 reference

10 September 2017

Masaki Mori

12

1 reference

10 September 2017

Koshi Mimori

13

1 reference

10 September 2017

language of work or name

English

0 references

publication date

15 September 2012

1 reference

10 September 2017

1 reference

10 September 2017

33

1 reference

10 September 2017

12

1 reference

10 September 2017

2391-2397

1 reference

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

10 September 2017

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS288

Defining the role of mTOR in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS288

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS288

Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS288

Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS288

Everolimus for advanced pancreatic neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS288

Phase 1/2 study of everolimus in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS288

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS288

AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS288

mTOR signaling pathway is a target for the treatment of colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS288

mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS288

Targeted inhibition of mammalian target of rapamycin signaling inhibits tumorigenesis of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS288

MicroRNA signatures in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS288

A microRNA expression signature of human solid tumors defines cancer gene targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS288

MicroRNA-125a-5p is an independent prognostic factor in gastric cancer and inhibits the proliferation of human gastric cancer cells in combination with trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS288

Analysis of the gene-expression profile regarding the progression of human gastric carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS288

Microarray data normalization and transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS288

Differential expression of miR-144* as a novel fecal-based diagnostic marker for colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS288

The miR-144/451 locus is required for erythroid homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS288

A dicer-independent miRNA biogenesis pathway that requires Ago catalysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS288

Human tumor microRNA signatures derived from large-scale oligonucleotide microarray datasets

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS288

DCAMKL-1 regulates epithelial-mesenchymal transition in human pancreatic cells through a miR-200a-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS288

Rapamycin regulates endothelial cell migration through regulation of the cyclin-dependent kinase inhibitor p27Kip1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS288

mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS288

End points in advanced colon cancer clinical trials: a review and proposal

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS288

Lymph node evaluation and survival after curative resection of colon cancer: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCARCIN%2FBGS288

21 January 2018

Identifiers

DOI

10.1093/CARCIN/BGS288

1 reference

10 September 2017

1 reference